Skip to main content
Premium Trial:

Request an Annual Quote

Swiss Organizations Team up with Roche in Translational Research

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – The University of Geneva, Geneva University Hospitals, and the SIB Swiss Institute of Bioinformatics today announced a strategic collaboration with Roche in translational medical research.

The deal will initially be directed at basic research, bioinformatics, and biomarker development in cardiology, hematology, pathology, and applied human toxicology, SIB said. It added that the partnership will leverage "the scientific excellence in Geneva" and Roche's internal research to develop better medical diagnostics and treatments tailored to patients.

In a statement, Jacky Vonderscher, global head of Translational Research Sciences at Roche, said that Geneva is a hub of specialists in proteomics and bioinformatics "with a strong translational set-up between labs and the clinic. This close link between diverse disciplines is absolutely key to better understand the diseases at the molecular level and ultimately to discover new diagnostic and therapeutic interventions."

Projects will be chosen based on mutual interests of the partners. Financial and other terms of the deal were not disclosed.

"The collaboration with Geneva is really important to us as it will focus on the predictability of safety assessment," Thomas Singer, global head of Non Clinical Safety at Roche, said. "The ability to forecast the side effects of medicine greatly grows with the use of human cells revealing the pharmacological and toxicological pathways."

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.